Synopsis:- Shares of a diagnostic healthcare company rose nearly 2% after announcing March 20, 2026, as the record date for a 3:1 bonus issue. The company also reported strong operational momentum, with patient volumes rising 9% and test volumes increasing 8%, supported by improving margins.
The shares of the prominent healthcare company gained up to 2 percent in today’s trading session after the board of directors set a record date for its 3:1 bonus share issue. With a market capitalization of Rs 9,560.92 crore, the shares of Metropolis Healthcare Ltd were trading at Rs 1,844.60 per share, increasing around 1.55 percent as compared to the previous closing price of Rs 1,816.40 apiece
Bonus Issue
The shares of Metropolis Healthcare Ltd have seen positive movement after the company fixed March 20, 2026, as the record date, for bonus equity shares in a 3:1 ratio. Under this plan, investors will receive three new fully paid-up shares of face value Rs 2 each for every existing share held. The bonus issue is expected to improve liquidity in the stock and attract greater investor participation. Moreover, if an investor holds 1,000 shares, they will receive 3,000 bonus shares, increasing their total holding to 4,000 shares after the bonus issue.
Financial & Other Highlights
Looking at the company’s financial performance, it reported strong growth in Q3FY26. Revenue rose about 35% to Rs 406 crore from Rs 323 crore in Q3FY25. Meanwhile, net profit increased around 38%, reaching Rs 42 crore compared to Rs 31 crore in the same quarter last year, reflecting improved operational performance.
Over the past year, Metropolis Healthcare has shown steady operational improvement. Operating profit increased from ₹72 crore in December 2024 to ₹95 crore in December 2025, reflecting stronger business performance. Meanwhile, operating profit margin improved from 22% to around 23% during the same period, indicating better cost management and improved operational efficiency.
Metropolis Healthcare reported steady growth in Q3FY26, supported by higher patient and test volumes. Patient volume rose 9% to 3.32 million, while test volumes increased 8% to 6.99 million. Additionally, revenue per patient and revenue per test grew around 6%, reflecting improved service mix and stronger contribution from specialty and TruHealth segments.
As of December 2025, promoters held a 48.87% stake in Metropolis Healthcare, reflecting stable ownership. Institutional participation remained strong, with DIIs holding 34.73% and FIIs owning 11.68% of the company. Meanwhile, public shareholding stood at 4.69%. The shareholding pattern indicates significant domestic institutional confidence in the company’s long-term growth prospects.
Metropolis Healthcare Limited is one of India’s leading diagnostic service providers, offering a wide range of pathology and laboratory testing services. The company operates an extensive network of laboratories and collection centers across India and overseas, focusing on advanced diagnostics, quality testing, and preventive healthcare solutions for patients and medical professionals.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
